Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioLineRx's BL-1040 trial passes safety review

This article was originally published in Clinica

Executive Summary

BioLineRx's phase I/II study of its BL-1040 liquid polymer device is on track to report in the third quarter of this year, following approval from an independent safety monitoring board. The polymer treats myocardial infarction by transforming into a gel-like scaffold following its injection into damaged heart tissue. The Jerusalem, Israel-based company may now enrol an additional 25 patients into the trial, following safety assessments of the first five patients to complete at least 30 days of follow-up following treatment with BL-1040 without experiencing side-effects. Interim results presenting six-month data from the first five patients are expected during the second quarter. BL-1040 is being developed as a class III medical device under the US FDA's premarketing approval (PMA) pathway; if all goes well, the product could be approved in the US by 2012.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel